Moroncini Gianluca, Calogera Giovanni, Benfaremo Devis, Gabrielli Armando
Clinica Medica, Dipartimento di Scienze Cliniche e Molecolari, Universita Politecnica delle Marche, Ancona, Italy.
Curr Pharm Biotechnol. 2017;18(12):1008-1016. doi: 10.2174/1389201019666171226152448.
The use of biologic agents in systemic immune-mediated diseases has dramatically increased in recent years, replacing conventional immunosuppressive strategies that are characterized by unspecific mechanisms of action and burdened with serious adverse effects. Biologic drugs have selective action towards specific targets, with considerable steroid-sparing effect. They are used nowadays to induce remission or treat specific organ involvements in systemic autoimmune diseases.
In this review, we will discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the conventional drugs.
近年来,生物制剂在全身性免疫介导疾病中的应用显著增加,取代了传统的免疫抑制策略,传统策略具有非特异性作用机制且伴有严重不良反应。生物药物对特定靶点具有选择性作用,具有显著的激素节省效应。如今,它们被用于诱导全身性自身免疫性疾病的缓解或治疗特定器官受累情况。
在本综述中,我们将讨论支持在这些疾病中使用生物制剂的科学证据,特别强调与传统药物相比它们的疗效和安全性。